Shares of
Quest Diagnostics Incorporated (NYSE:DGX) continue to show
strong momentum as they are being acquired by leading financial institutions including
Mizuho Securities USA LLC, ING Groep NV,
Versor Investments LP, and
Arjuna Capital. This comes after the
stock's underperformance compared to competitors.
Investors have met with
slowing returns on capital, but acquisition news has kept the stock aloft. In recent developments, Quest Diagnostics announced a
quarterly cash dividend of $0.75, maintaining
shareholder returns. It also announced to
launch a bird flu test at the end of October. The company is committed to enhancing access to
diagnostic innovation, and recently completed its acquisition of
LifeLabs. Quest Diagnostics also reported
second and
third quarter financial results and raised
guidance for 2024. The revenue and earnings exceeded expectations due to high demand for diagnostic tests, and the company's decision to acquire outreach laboratory services business from University Hospitals and OhioHealth. Quest Diagnostics continues its expansion in Canada with
LifeLabs buyout, and it is partnering with multiple organizations to produce and develop a range of diagnostic tests.
Quest Diagnostics DGX News Analytics from Tue, 09 Jan 2024 08:00:00 GMT to Sat, 16 Nov 2024 14:38:06 GMT -
Rating 7
- Innovation 0
- Information 6
- Rumor 3
